Assistant Professor of Chemistry (Organic)
Johns Hopkins School of Medicine (Postdoc)
University of Alberta (Ph.D.)
Dr. Shi's research is in the application of organic and medicinal chemistry to explore biological and pharmaceutical potential of underexplored bioactive natural products, in particular glycoconjugates. The long-term goal of his laboratory is to design new chemical entities derived from the natural products with an improved synthetic and/or therapeutic profile for drug discovery. For more current information, please check his group website listed above.
(Corresponding author denoted by *; Undergraduate denoted by §)
Zong, G.†; Hu, Z.†; O'Keefe, S.;# Tranter, D.;# Iannotti, M. J.;# Baron, L.;# Hall, B.;# Corfield, K.;# Paatero, A.; Henderson, M. J.;# Roboti, P.;# Zhou, J.; Sun, X.; Govindarajan, M.; Rohde, J.; Blanchard, N.; Simmonds, R.;* Inglese, J.;* Du, Y.;* Demangel, C.;* High, S.;* Paavilainen, V. O.;* Shi, W. Q.* “Ipomoeassin F binds Sec61α to inhibit protein translocation”, J. Am. Chem. Soc. 2019, 141, 8450–8461. (†, # Equal contribution)
Zong, G.; Sun, X.; Bhakta, R.§; Whisenhunt, L.; Hu, Z.; Wang, F.; Shi, W. Q.* “New insights into structure–activity relationship of ipomoeassin F from its bioisosteric 5-oxa/aza analogues”, Eur. J. Med. Chem. 2018, 144, 751–757.
Zong, G.†; Hirsch, M.†; Mondrik, C.§; Hu, Z.; Shi, W. Q.* “Design, synthesis and biological evaluation of fucose-truncated monosaccharide analogues of ipomoeassin F”, Bioorg. Med. Chem. Lett. 2017, 27, 2752–2756. († Equal contribution)
Head, S.; Shi, W. Q.; Yang, E. J.; Nacev, B. A.; Hong, S. Y.; Pasunooti, K.; Li, R. J.; Shim, J. S.; Liu, J. O.* “Simultaneous targeting of NPC1 and VDAC1 by itraconazole leads to synergistic inhibition of mTOR signaling and angiogenesis”, ACS Chem. Biol. 2017, 22, 174–182.
Zong, G.; Whisenhunt, L.; Hu, Z.; Shi, W. Q.* “Synergistic contribution of tiglate and cinnamate to cytotoxicity of ipomoeassin F”, J. Org. Chem. 2017, 82, 4977−4985.
Zong, G.; Aljewari, H.; Hu, Z.; Shi, W. Q.* “Revealing the pharmacophore of ipomoeassin F through molecular editing”, Org. Lett. 2016, 18, 1674−1677.
Zong, G.; Barber, E.; Aljewari, H.; Zhou, J.; Hu, Z.; Du, Y.; Shi, W. Q.* “Total synthesis and biological evaluation of ipomoeassin F and its unnatural 11R-epimer” J. Org. Chem. 2015, 80, 9279−9291.
Head, S.; Shi, W.; Zhao, L.; Gorshkov, K.; Pasunooti, K.; Chen, Y.; Deng, Z,; Li, R.; Shim, J. S.; Tan, W.; Hartung, T.; Zhang, J.; Zhao, Y.; Colombini, M.; Liu, J. O.* “The antifungal drug itraconazole targets VDAC1 to modulate the AMPK/mTOR signaling axis in endothelial cells”, Proc. Natl. Acad. Sci. U.S.A. 2015, 112, E7276–7285.
Shi, W.; Nacev, B. A.; Aftab, B.; Head, S.; Rudin, C. M.; Liu, J. O.* “Itraconazole side chain analogs: structure–¬¬activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and Hedgehog signaling” J. Med. Chem. 2011, 54, 7363–7374.
Shi, W.; Marcus, S. L.; Lowary, T. L.* “Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans” Bioorg. Med. Chem. 2011, 19, 603–612.
Shi, W.; Nacev, B. A.; Bhat, S.; Liu, J. O.* “Impact of absolute stereochemistry on the antiangiogenic and antifungal activities of itraconazole” ACS Med. Chem. Lett. 2010, 1, 155–159.
Shi, W.; Coleman, R. S.; Lowary, T. L.* “Synthesis and DNA-binding affinity studies of glycosylated intercalators designed as functional mimics of the anthracycline antibiotics” Org. Biomol. Chem. 2009, 7, 3709–3722.
Shi, W.; Qian, X.;* Zhang, R.; Song, G. “Synthesis and quantitative structure–activity relationships of new 2,5-disubstituted-1,3,4-oxadiazoles” J. Agric. Food Chem. 2001, 49, 124–130.